Consolidated Statements of Earnings (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Net revenue
Product revenue	$ 98,036,000	$ 86,589,000	$ 77,419,000
License and collaboration revenue	350,000	3,367,000	1,024,000
Total net revenue	98,386,000	89,956,000	78,443,000
Product costs and operating expenses:
Cost of goods sold	32,561,000	29,844,000	26,465,000
Collaboration expenses	0	0	175,000
Research and development	11,870,000	10,240,000	9,524,000
Clinical and regulatory	4,358,000	4,332,000	3,551,000
Sales and marketing	25,777,000	24,126,000	23,188,000
General and administrative	6,522,000	4,997,000	5,183,000
Litigation	0	0	(3,529,000)
Amortization of purchased technology and intangibles	1,393,000	831,000	304,000
Total product costs and operating expenses	82,481,000	74,370,000	64,861,000
Operating earnings	15,905,000	15,586,000	13,582,000
Other earnings (expenses):
Interest earnings	0	16,000	38,000
Interest expense	(13,000)	(13,000)	(20,000)
Foreign exchange gain (loss)	0	110,000	(42,000)
Earnings before income taxes	15,892,000	15,699,000	13,558,000
Income tax benefit (expense)	(5,983,000)	(5,960,000)	7,819,000
Net earnings	$ 9,909,000	$ 9,739,000	$ 21,377,000
Basic net earnings per common share (in dollars per share)	$ 0.62	$ 0.59	$ 1.30
Diluted net earnings per common share (in dollars per share)	$ 0.60	$ 0.57	$ 1.26
Shares used in computing basic net earnings per common share (in shares)	16,003,932	16,638,078	16,478,206
Shares used in computing diluted net earnings per common share (in shares)	16,455,729	17,183,579	17,008,218